MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemiaF J Giles
HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College Dublin, Galway, Ireland
Leukemia 27:113-7. 2013
..MK-0457 has important activity in patients with leukemias expressing the highly resistant T315I BCR-ABL mutation...
- Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
F J Giles
HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College, Dublin, Ireland
Leukemia 27:107-12. 2013
..Further significant improvements in therapy are required for patients who are resistant or intolerant to imatinib...
- Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia
Francis Giles
HRB Clinical Research Facility, National University of Ireland Galway and Trinity College Dublin, Dublin, Ireland
Eur J Clin Invest 42:1016-26. 2012
..imatinib...
- Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
F J Giles
HRB Clinical Research Facility, National University of Ireland Galway and Trinity College Dublin, University Road, Galway, Ireland
Leukemia 26:959-62. 2012
..Nilotinib has significant efficacy in patients with BP CML, but given the limited long-term survival of these patients, novel agents are needed...
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phaseFrancis J Giles
Department of Leukemia, M D Anderson Cancer Center, University of Texas, P O Box 428, Houston, TX 77030, USA
Leuk Res 27:1091-6. 2003
..Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML...
- Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia
Francis J Giles
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
Cancer 100:1449-58. 2004
..OSI-211 is a low-clearance, unilamellar liposomal formulation of a water-soluble camptothecin analogue, lurtotecan. OSI-211 has significant activity in severe combined immunodeficient mouse models of human leukemia...
- Novel therapies for patients with chronic myeloid leukemia
Francis J Giles
Department of Leukemia, Box 428, University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
Expert Rev Anticancer Ther 4:271-82. 2004
....
- A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia
Francis J Giles
Department of Leukemia, M D Anderson Cancer Center, The University of Texas, Box 428, 1400 Holcombe Boulevard, Houston, TX 77030, USA
Leuk Res 28:353-7. 2004
..Six patients (35%) achieved complete remission. Seven patients (41%) developed grade 3 or 4 diarrhea. FTA was effective and warrants further study in patients with refractory AML...
- A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy
Francis J Giles
M D Anderson Cancer Center, Department of Leukemia, The University of Texas, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
Leuk Res 28:559-65. 2004
..A major impact of Iseganan on reducing stomatitis, UOM, or its clinical sequelae in patients receiving stomatotoxic therapy was not detected on this study...
- Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia
Francis Giles
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
Clin Cancer Res 11:7817-24. 2005
..A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease...
- Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia
Francis J Giles
Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Curr Mol Med 5:615-23. 2005
..We review the current data on imatinib in CML, the criteria for diagnosis of imatinib resistance, and the mechanisms that underlie such resistance in CML...
- The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Francis J Giles
Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
Leuk Res 30:801-11. 2006
..AG-01736 had minimal biologic or clinical activity in this elderly patient population...
- Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions
Francis J Giles
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
Ann Pharmacother 37:1182-5. 2003
..To assess whether the addition of a brief course of intravenous corticosteroids reduces the incidence of infusion-related adverse events associated with gemtuzumab ozogamicin (GO) administration...
- A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial)
Francis J Giles
Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
Leuk Lymphoma 44:1165-72. 2003
..6 and 2.0 (P = 0.0131). Iseganan was well tolerated; no systemic absorption was detected. Iseganan is safe and may be effective in reducing UOM and its clinical sequelae...
- Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias
Francis J Giles
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 21:1050-6. 2003
..Troxacitabine has significant single-agent activity. This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan...
- Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome
Francis Giles
Department of Leukemia, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA
Acta Haematol 108:164-7. 2002
- Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival
Francis J Giles
Department of Leukaemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Br J Haematol 119:38-45. 2002
..0002, Cox proportional hazard model). A multivariate model based on Cox-2 and degree of splenomegaly was developed for survival in patients with early CP CML. Agents that inhibit Cox-2 activity merit investigation in patients with CP CML...
- SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
Francis J Giles
Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
Blood 102:795-801. 2003
..Studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML/MDS...
- Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases
Francis J Giles
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Cancer 97:1920-8. 2003
..SU5416 is a small-molecule RTK inhibitor (RTKI) that targets VEGFR-2, c-kit, and fms-related tyrosine kinase Flk2...
- New drugs in acute myeloid leukemia
Francis J Giles
Section of Developmental Therapeutics, Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
Curr Oncol Rep 4:369-74. 2002
..Those agents targeting vascular endothelial growth factor are also briefly reviewed...
- Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
Francis J Giles
Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 21:1722-7. 2003
..A prospective, randomized study was conducted in patients aged 50 years or older with untreated, adverse karyotype, acute myeloid leukemia (AML) to assess troxacitabine-based regimes as induction therapy...
- Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia
Francis J Giles
Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
Cancer Chemother Pharmacol 52:223-8. 2003
..The combination of fludarabine and cyclophosphamide (FC) is highly active in patients with chronic lymphocytic leukemia (CLL). Infection is a serious toxicity of the FC regimen...
- Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia
Francis J Giles
Department of Leukemia, Box 428, University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
Expert Rev Anticancer Ther 2:630-40. 2002
..Gemtuzumab ozogamicin-based combinations should not be prescribed outside the research setting until further data is available...
- Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse
Francis Giles
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, 77230 1402, USA
Br J Haematol 134:58-60. 2006
..The EPI is reproducible and useful...
- Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
F J Giles
Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
Leukemia 23:1698-707. 2009
..This paper reviews the various kinases inhibited by imatinib, nilotinib and dasatinib, and describes the potential impact of kinase inhibition on the efficacy and safety of each agent...
- New directions in the treatment of imatinib failure and/or resistance
Francis J Giles
Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
Semin Hematol 46:S27-33. 2009
....
- Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse
Francis Giles
Cancer Therapy and Research Center CTRC at The University of Texas Health Science Center, San Antonio, TX 78229, USA
Blood 114:4027-33. 2009
..The DSMB subsequently approved a revised protocol with laromustine dose reduction and recombinant growth factor support. The study was registered as NCT00112554 at http://www.clinicaltrials.gov...
- Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia
F J Giles
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
J Clin Oncol 19:762-71. 2001
..To investigate the toxicity profile, activity, and pharmacokinetics of a novel L-nucleoside analog, troxacitabine (BCH-4556), in patients with advanced leukemia...
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyF J Giles
Cancer Treatment and Research Center at The University of Texas Health Science Center, Institute for Drug Development, San Antonio, TX 78229, USA
Leukemia 24:1299-301. 2010
..Nilotinib is an effective therapy in CML-CP and -AP following failure of both imatinib and dasatinib therapy...
- Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study
Francis J Giles
HRB Clinical Research Facility, National University of Ireland, Galway and Trinity College, Dublin, Ireland
Expert Rev Hematol 3:665-73. 2010
..Nilotinib's clinical superiority over imatinib, as demonstrated by the ENESTnd study, has established it as an agent that we believe is a significant further step towards the cure of CML...
- A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study
F J Giles
The International Oncology Study Group, Houston, Texas 77401, USA
Leuk Lymphoma 37:367-77. 2000
..In conclusion if seems that there is no apparent early survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as first-line CML therapy...
- Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol
F J Giles
The International Oncology Study Group, Houston, Texas 77401, USA
Am J Hematol 63:125-30. 2000
..In 15% of septic episodes positive blood cultures were obtained. Overt cardiotoxicity was seen in two patients. CEVAD as used in this study was not more effective than VAD in terms of overall response rate or survival...
- Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia
Francis J Giles
Professor of Medicine, and Chief, Division of Hematology and Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
Semin Oncol 35:S1-17; quiz S18-20. 2008
..Other areas such as microRNA profiling and DNA methylation patterns are likely to provide important information...
- Plasma-based testing as a new paradigm for clinical testing in hematologic diseases
Francis J Giles
University of Texas Health Science Center, Division of Hematology and Medical Oncology, San Antonio, TX 78229, USA
Expert Rev Mol Diagn 7:615-23. 2007
..Unlike solid tumors, currently available data suggest that in hematologic diseases, plasma is superior to cells in detecting molecular abnormalities...
- A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study
F J Giles
International Oncology Study Group, Houston, Texas, USA
Leuk Lymphoma 40:95-103. 2000
....
- A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
Francis Giles
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
Clin Cancer Res 12:4628-35. 2006
..LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle...
- MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Francis J Giles
Department of Leukemia, M D Anderson Cancer Center, 1400 Holcombe Blvd, Box 428, Houston, TX 77030, USA
Blood 109:500-2. 2007
..The observation of responses in 3 patients with T315I phenotype-refractory CML or Ph-positive ALL, at doses of MK-0457 associated with no significant extramedullary toxicity, is very encouraging...
- Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia
Francis Giles
The University of Texas M D Anderson Cancer Center, Department of Leukemia, Houston, TX 77030, USA
J Clin Oncol 25:25-31. 2007
..A multicenter phase II study of cloretazine was conducted in patients 60 years of age or older with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)...
- The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
Francis J Giles
Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX 77030, USA
Br J Haematol 136:624-7. 2007
..001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy...
- PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia
Francis J Giles
The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
Leuk Res 31:891-7. 2007
..One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM...
- Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia
Francis J Giles
Department of Leukemia, M D Anderson Cancer Center, University of Texas, Box 428, Houston, TX 77030, USA
Leuk Res 27:1077-83. 2003
..Based on these clinical, pharmacokinetic, and pharmacodynamic data, Triapine warrants further study in patients with hematologic malignancies...
- Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML
Francis J Giles
Division of Hematology and Medical Oncology, San Antonio, TX 78229, USA
Leuk Lymphoma 48:1064-6. 2007
- High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens
M Beran
Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
Cancer 92:1999-2015. 2001
..Because the results of standard regimens have been disappointing, high-dose chemotherapeutic regimens were investigated recently. In the absence of randomized trials, the relative merits of various treatment regimens are unknown...
- Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia
E H Estey
Department of Leukemia Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Blood 94:2230-5. 1999
..Our data suggest that lipoATRA is an effective means of producing molecular CR in newly diagnosed APL...
- Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase
F J Giles
Department of Leukemia; University of Texas MD Anderson Cancer Center Houston, Texas 77030, USA
Leuk Lymphoma 41:309-19. 2001
..01). In conclusion, the addition of intensive chemotherapy may improve survival in patients with CML who have not obtained an adequate cytogenetic response on an IFN-alpha-based regimen...
- Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
E H Estey
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 98:3575-83. 2001
..It is unlikely that, as given here, either FA or TA is, in general, superior to IA, highlighting the need for new treatments...
- High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome
S Verstovsek
Department of Leukemia, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
Leuk Lymphoma 42:511-6. 2001
..The role of Tie-1 overexpression in the reported increased vascularity in the bone marrow of AML and MDS patients requires further investigation...
- Antiangiogenic therapy in leukemia
D A Thomas
Department of Leukemia, M D Anderson Cancer Center, Houston, Tex 77030, USA
Acta Haematol 106:190-207. 2001
..The role of angiogenesis in hematological malignancies, the rationale for the use of angiosuppressive therapy for these entities, and the status of novel antiangiogenic agents in clinical trials are discussed...
- Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
H M Kantarjian
Leukemia Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 19:1414-20. 2001
..Myelosuppression and infection remain the most significant complications of therapy in CLL...
- Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
Apostolia Tsimberidou
Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
Leuk Res 27:893-7. 2003
..CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML...
- Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
Jorge Cortes
Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
Cancer Chemother Pharmacol 50:497-500. 2002
..CONCLUSIONS: MTA was moderately effective and associated with significant toxicity in patients with refractory AML...
- Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome
B S Dabaja
Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, Texas 77030, USA
Leuk Lymphoma 42:329-37. 2001
..0017). In conclusion the hyper CVXD regimen has a relatively high response rate, significant toxicity and a moderate impact on survival in RS...
- Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase
H M Kantarjian
Department of Leukemia, M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 92:2501-7. 2001
..The association of treatment response with survival was evaluated by multivariate and landmark analyses...
- Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome
S Verstovsek
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA
Leukemia 15:1165-70. 2001
..No significant correlation was observed between HGF levels and complete remission rate or duration. In the multivariate analysis HGF retained its significance as prognostic factor in AML (P = 0.02), along with age (P = 0.0005)...
- The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies
F J Giles
Department of Leukemia, M D Anderson Cancer Center, Houston, Texas 77030, USA
Oncologist 6:32-9. 2001
....
- Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias
H M Amin
Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Leukemia 19:1567-72. 2005
..These data also suggest that MDS classification schemes should take into account the percentage of blasts in PB differently from the percentage of blasts in BM...
- Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside
Elihu H Estey
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Blood 99:4343-9. 2002
..Thus, there is little evidence to suggest that GO with or without IL-11 should be used instead of IA in older patients with newly diagnosed AML or myelodysplastic syndrome...
- Rituximab dose-escalation trial in chronic lymphocytic leukemia
H Kantarjian
Leukemia Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 19:2165-70. 2001
..Efficacy of rituximab was also significant in this group of patients...
- Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
H M Kantarjian
Departments of Leukemia, Bioimmunotherapy, Biostatistics, and Blood and Bone Marrow Transplantation, M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 18:3513-21. 2000
....
- Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
M Beran
Departments of Leukemia and Molecular Hematology, and Division of Laboratory Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 17:2819-30. 1999
..To evaluate the efficacy and safety of the combination of topotecan and cytarabine in patients with myelodysplastic syndromes (MDSs) and chronic myelomonocytic leukemia (CMML)...
- Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation
F J Giles
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
Cancer 92:406-13. 2001
..Hepatic venoocclusive disease (VOD) has been reported in patients who have undergone stem cell transplantation (SCT) after Mylotarg therapy. Outside of the SCT setting, VOD has been associated very rarely with cytotoxic therapy...
- Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma
K R Kelly
Department of Medicine, The Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX 78229, USA
Oncogene 31:3023-38. 2012
..Furthermore, reovirus infection can be used as a promising approach to augment the anti-myeloma activity of bortezomib by promoting additional stress to the endoplasmic reticulum of MM cells...
- Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia
J R Beck
Information Technology Program, Baylor College of Medicine, Houston, Texas 77030, USA
Leuk Lymphoma 41:117-24. 2001
..Based on data from the French study, cytarabine added to IFN-alpha substantially improves the cost-effectiveness of initial therapy for early chronic phase CML...
- Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival
F J Giles
Departments of Leukemia, Biostatistics, and Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 61, Houston, TX 77030, USA
Leuk Lymphoma 42:67-73. 2001
....
- Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance
F Ravandi
Department of Leukemia, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 91:1964-72. 2001
..The influence of these cellular proteins and caspase-3 activity on apoptosis in CML is complex and merits further investigation...
- Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome
Karen W L Yee
Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
Leuk Res 30:813-22. 2006
..The recommended phase II regimen is Triapine 105 mg/m2/day followed by ara-C 600 mg/m2/day for 5 consecutive days every 3-6 weeks...
- Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome
Srdan Verstovsek
Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA
Br J Haematol 118:151-6. 2002
..These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS...
- Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia
Francis J Giles
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 8:2134-41. 2002
....
- Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
Stefan Faderl
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
Blood 108:45-51. 2006
..However, survival does not appear to be improved compared with other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation...
- Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism
H Zhang
Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Leukemia 22:1191-9. 2008
..Our results suggest that PEITC is a promising compound capable of killing Gleevec-resistant CML cells through a ROS-mediated mechanism and warrants further investigations...
- The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1
J Pan
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Leukemia 21:1395-404. 2007
..Our data establish EXEL-0862 as a solid candidate for the targeted treatment of patients with FIP1L1-PDGFR-alpha-positive HES...
- Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
D Mahalingam
Department of Medicine, Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, 7979 Wurzbach Road, San Antonio, TX 78245, USA
Br J Cancer 105:1563-73. 2011
..We hypothesised that inhibition of PIM kinase activity with SGI-1776, a novel small molecule inhibitor of PIM kinase activity, would reduce the viability of renal cell carcinoma (RCC) cells and enhance the activity of sunitinib...
- Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
Yesid Alvarado
Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA
Cancer Chemother Pharmacol 51:87-90. 2003
..CONCLUSIONS: The addition of Mylotarg to idarubicin and ara-C is feasible. MIA has significant activity in patients with refractory AML. Hepatotoxicity and VOD are significant toxicities of Mylotarg-based combinations...
- Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
Alvaro Aguayo
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
Cancer 95:1923-30. 2002
..CONCLUSIONS: Plasma VEGF levels have prognostic significance in patients with AML. The lack of clinical relevance of VEGF levels in patients with MDS suggests some biologic difference between AML and MDS...
- Troxacitabine-based therapy of refractory leukemia
Francis J Giles
Section of Developmental Thereputics, The University of Texas M D Anderson Cancer Center, Department of Lukemia, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030 4095, USA
Expert Rev Anticancer Ther 2:261-6. 2002
..Phase II studies in patients with refractory lymphoproliferative diseases are ongoing. Troxacitabine merits further study in patients with hematological malignancies...
- Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
Apostolia M Tsimberidou
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
Cancer Chemother Pharmacol 52:449-52. 2003
..Grade 3/4 toxicities, including sepsis, neutropenic fever, and nausea/vomiting, were equivalent with MFAC and IA. CONCLUSIONS: Post-remission therapy with MFAC is feasible and well tolerated in patients with AML...
- Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
Stefan Faderl
Department of Leukemia, Box 428, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Blood 105:940-7. 2005
..The combination of clofarabine with ara-C is safe and active. Cellular pharmacology data support the biochemical modulation strategy...
- Therapeutic choices in younger patients with chronic myelogenous leukemia
H M Kantarjian
Department of Leukemia, M D Anderson Cancer Center, Houston, Texas, USA
Cancer 89:1647-58. 2000
..Both therapies may be suitable for younger patients. The authors reviewed current data to assist in prioritizing these modalities in an individual patient...
- Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia
F J Giles
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA
Leuk Lymphoma 37:87-95. 2000
..We conclude that oral idarubicin is sufficiently safe and active to warrant phase II studies investigating it as part of interferon-based regimens in patients with advanced CML...
- Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia
M Talpaz
Department of Bioimmunotherapy, M. D. Anderson Cancer Center, Houston, TX, USA
Blood 98:1708-13. 2001
..The results show that PEG IFN-alpha-2b is easier to deliver (once weekly), better tolerated, and perhaps more effective than IFN-alpha...
- Troxacitabine activity in extramedullary myeloid leukemia
Yesid Alvarado
Department of Leukemia, M.D. Anderson Cancer Center, The University of Texas, Houston 77030, USA
Hematology 7:179-85. 2002
..Troxacitabine-based therapy had significant antileukemic activity in extramedullary myeloid leukemias and warrants further investigation in this clinical situation...
- The role of gemtuzumab ozogamicin in acute leukaemia therapy
Apostolia Maria Tsimberidou
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Br J Haematol 132:398-409. 2006
..The future of GO is its use in combination with other cytotoxic agents. Ongoing clinical trials may better define the role of GO combinations, particularly in untreated AML...
- Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
Karen W L Yee
Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Clin Cancer Res 11:6615-24. 2005
..CONCLUSION: Further assessment of ABT-751, especially in combination with other agents, in patients with acute leukemias is warranted...
- Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment
Apostolia Maria Tsimberidou
Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Leuk Res 27:375-80. 2003
..No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study...
- Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
Hagop M Kantarjian
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
Blood 100:1590-5. 2002
..We conclude that imatinib mesylate effectively controlled CML that recurred after allogeneic SCT, but it was associated with side effects including myelosuppression and recurrence of severe GVHD...
- Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
Stefan Faderl
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
Blood 101:3413-5. 2003
..The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses...
- Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors
Dan Jones
Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 113:985-94. 2008
..Patterns of KD mutations in Philadelphia chromosome (Ph)-positive acute lympho- blastic leukemia (ALL) are less well studied...
- New agents in myelodysplastic syndromes
Elias J Jabbour
Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77063, USA
Curr Hematol Rep 4:191-9. 2005
..Further development of rational therapies and improvements in the outcome of patients with MDS are likely to emerge from an increased understanding of the pathophysiology of these diseases...
- Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Deborah A Thomas
Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
Blood 103:4396-407. 2004
..Molecular CRs were achieved in both groups (SCT or no SCT). Outcome with hyper-CVAD and imatinib mesylate appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed...
- Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy
Jennifer S Carew
The Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, 14960 Omicron Drive, San Antonio, TX 78245, USA
Cancer Lett 269:7-17. 2008
..Here we summarize the different mechanisms of HDAC inhibitor-induced apoptosis and discuss their use in combination with other anticancer agents...
- Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
Karen W L Yee
Authors' Affiliations: Departments of Leukemia and Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, Texas
Clin Cancer Res 12:5165-73. 2006
..Studies of everolimus in combination with therapeutic agents directed against other components of the phosphatidylinositol 3-kinase/Akt/mTOR pathway are warranted...
- Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia
Efrosyni Apostolidou
Department of Leukemia, M.D. Anderson Cancer Center, University of Texas, Box 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
Leuk Res 27:887-91. 2003
..The inclusion of CSA in a gemtuzumab ozogamicin-containing regimen is feasible. The MDAC regimen was associated with significant toxicity in a cohort of patients with very advanced AML...
- The emerging role of angiogenesis inhibitors in hematologic malignancies
Francis J Giles
Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
Oncology (Williston Park) 16:23-9. 2002
..This review will summarize several angiogenesis inhibitors in clinical development...
- Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia
Francis J Giles
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 20:656-64. 2002
..To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia...
- Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
Hagop M Kantarjian
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Blood 99:3547-53. 2002
..04), and lower 4-week induction mortality (4% versus 15%, P =.07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML...
- Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
Deborah A Thomas
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
Cancer 106:1569-80. 2006
..CONCLUSIONS: The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL, particularly in elderly patients...
- Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia
Gary J Schiller
Cancer Therapy and Research Center at the University of Texas Health Science Center, 7979 Wurzbach Rd, Mail Code 8026, Urschel Tower, Suite 600, San Antonio, TX 78229, USA
J Clin Oncol 28:815-21. 2010
..CONCLUSION Laromustine has significant single-agent activity in elderly patients with poor-risk AML. Adverse events are predominantly myelosuppressive or respiratory. Response rates are consistent across a spectrum of poor-risk features...
- Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data
Hagop M Kantarjian
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 98:2636-42. 2003
..This was most likely because approximately 90% of patients receiving IFN-alpha plus ara-C changed to imatinib therapy after a median of 8 months into therapy...
- Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease
Apostolia M Tsimberidou
Department of Leukemia, MD Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
Leuk Lymphoma 44:1719-25. 2003
..Human antimouse antibody (HAMA) and/or human antiricin antibody (HARA) development was documented in 2 patients. Anti-B4 blocked ricin was well tolerated but had limited activity in patients with residual CLL after chemotherapy...
- Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate
Hagop M Kantarjian
Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 8:2167-76. 2002
..Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML)...
- Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation
Nada Orsolic
Department of Leukemia, M.D. Anderson Cancer Center, The University of Texas, Houston 77030-4009, USA
Br J Haematol 124:727-38. 2004
..These data indicate that the combination of troxacitabine and IM has significant preclinical activity in advanced CML and that clinical evaluation of this combination is warranted...
